Tareq Issa Nassar, MD
Nephrology · San Antonio, TXNPI 1457630790
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,779 of the $4,793 with a category attached, or 99.7%. AstraZeneca accounts for 72.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $3,480 and has fallen 89.1% since, to $379 in 2025.
Across 5 payments — averaging $958.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Access Vascular Inc$650
- ZOLL Medical Corporation$379
- GSK$270
- Otsuka America Pharmaceutical, Inc.$13
Across 10 payments — averaging $11,997 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca AB$76K
- Janssen Research & Development, LLC$23K
- AstraZeneca$20K
- Astrazeneca UK Limited$1K
What the payments were for
- Consulting fees$4,779100%
- Food & beverage$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $3,480 |
| Access Vascular Inc | 1 | $650 |
| ZOLL Medical Corporation | 1 | $379 |
| GSK | 1 | $270 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HYDROPICC$650
- HYDROMID$650
- HYDROPICC DUAL LUMEN$650
- VANNAS DEEP ACCESS VASCULAR SCISSORS$650
- Defibrillator$379
- BENLYSTA$270
How this compares
$4,793 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XphozahTenapanor Hcl | 22 | $64,488 |
| VelphoroSucroferric Oxyhydroxide | 11 | $19,973 |
| AranespDarbepoetin Alfa In Polysorbat | 16 | $11,661 |
| ProcritEpoetin Alfa | 22 | $5,483 |
| Torsemide | 33 | $967 |
| Nifedipine ErNifedipine | 14 | $325 |
| Furosemide | 23 | $247 |
| Calcitriol | 11 | $229 |
| Losartan Potassium | 18 | $221 |
| Lisinopril | 13 | $78 |
| Amlodipine Besylate | 14 | $45 |
| Carvedilol | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Other nephrology in San Antonio
- Luis VelezSan Antonio$505K
- Rashid SharafSan Antonio$340K
- Carl DukesSan Antonio$238K
- Pablo PergolaSan Antonio$164K
- Varshasb BroumandSan Antonio$118K
- Shweta BansalSan Antonio$89K
- Rajeev NarayanSan Antonio$57K
- Anwar GergesSan Antonio$50K
- Matthew SchaeferSan Antonio$46K
- Kumar SharmaSan Antonio$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.